Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review
- PMID: 35094801
- PMCID: PMC8804335
- DOI: 10.1016/j.jval.2021.08.002
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review
Abstract
Objectives: Sickle cell disease (SCD) is a complex, chronic condition that impairs health-related quality of life of affected individuals and their caregivers. As curative therapies emerge, comprehensive cost-effectiveness models will inform their value. These models will require descriptions of health states and their corresponding utility values that accurately reflect health-related quality of life over the disease trajectory. The objectives of this systematic review were to develop a catalog of health state utility (HSU) values for SCD, identify research gaps, and provide future directions for preference elicitation.
Methods: Records were identified through searches of PubMed and Embase, Tufts Medical Center Cost-Effectiveness Analysis Registry, reference lists of relevant articles, and consultation with SCD experts (2008-2020). We removed duplicate records and excluded ineligible studies. For included studies, we summarized the study characteristics, methods used for eliciting HSUs, and HSU values.
Results: Five studies empirically elicited utilities using indirect methods (EQ-5D) (n = 3) and Short Form-6 Dimension (n = 2); these represent health states associated with general SCD (n = 1), SCD complications (n = 2), and SCD treatments (n = 3). Additionally, we extracted HSUs from 7 quality-adjusted life-years-based outcome research studies. The HSU among patients with general SCD without specifying complications ranged from 0.64 to 0.887. Only 36% of the HSUs used in the quality-adjusted life-year-based outcomes research studies were derived from individuals with SCD. No study estimated HSUs in caregivers.
Conclusions: There is a dearth of literature of HSUs for use in SCD models. Future empirical studies should elicit a comprehensive set of HSUs from individuals with SCD and their caregivers.
Keywords: cost-effectiveness analysis; health state utility; sickle cell disease; systematic review.
Copyright © 2021 ISPOR–The International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease.Qual Life Res. 2022 Sep;31(9):2729-2738. doi: 10.1007/s11136-022-03167-2. Epub 2022 Jun 17. Qual Life Res. 2022. PMID: 35715626 Free PMC article.
-
Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?Value Health. 2020 Mar;23(3):397-405. doi: 10.1016/j.jval.2019.12.004. Epub 2020 Feb 15. Value Health. 2020. PMID: 32197736
-
Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional study.J Patient Rep Outcomes. 2024 Sep 26;8(1):110. doi: 10.1186/s41687-024-00784-y. J Patient Rep Outcomes. 2024. PMID: 39325265 Free PMC article.
-
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.Value Health. 2019 Mar;22(3):267-275. doi: 10.1016/j.jval.2019.01.004. Value Health. 2019. PMID: 30832964 Review.
-
Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.Health Qual Life Outcomes. 2017 Jul 5;15(1):136. doi: 10.1186/s12955-017-0713-x. Health Qual Life Outcomes. 2017. PMID: 28679417 Free PMC article.
Cited by
-
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.PLoS One. 2022 Apr 28;17(4):e0267448. doi: 10.1371/journal.pone.0267448. eCollection 2022. PLoS One. 2022. PMID: 35482721 Free PMC article.
-
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9. Epub 2024 Apr 29. Pharmacoeconomics. 2024. PMID: 38684631 Free PMC article.
-
Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease.Qual Life Res. 2022 Sep;31(9):2729-2738. doi: 10.1007/s11136-022-03167-2. Epub 2022 Jun 17. Qual Life Res. 2022. PMID: 35715626 Free PMC article.
-
Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States : A Cost-Effectiveness Analysis.Ann Intern Med. 2024 Feb;177(2):155-164. doi: 10.7326/M23-1520. Epub 2024 Jan 23. Ann Intern Med. 2024. PMID: 38252942 Free PMC article.
References
-
- National Heart, Lung, and Blood Institute. Sickle Cell Disease. Accessed August 2, 2020. https://www.nhlbi.nih.gov/health-topics/education-and-awareness/sickle-cell
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials